We visited four of First REIT’s assets in Jakarta – three hospitals and a hotel-country club asset – on the 26th of September 2019. Three of the assets we visited, Siloam Hospitals Lippo Village (SHLV), Siloam Hospitals Kebon Jeruk (SHKJ) and Imperial Aryaduta Hotel & Country Club (IAHCC) have leases expiring in December 2021 (figure 2 and 3), the second earliest lease expiry in the portfolio. These three assets contribute 23.3% to FY18 revenue and are leased out to subsidiaries of Sponsor, PT Lippo Karawaci (LPKR). The last asset visited was Mochtar Riady Comprehensive Cancer Centre (MRCCC) which has a December 2025 lease expiry.
Company Background
First REIT’s (FIRT) S$1,345mn portfolio consists of 20 properties located in Indonesia (96.8%), Singapore (2.6%) and South Korea (0.6%). The assets are predominantly hospitals (78.6%), nursing homes (2.6%) and integrated developments (hospitals with adjoining retail/hotel facilities) (18.8%). LPKR and OUE Lippo Healthcare (OUELH) are co-sponsors of FIRT and hold 18.52% and 8.9% of the REIT, providing FIRT with two ROFR pipeline.
The Lease Structure
All of FIRT’s assets are leased out on master lease terms; the operations and hence profitability of the hospital depends on the hotel operators. 82% of the master leases are with LPKR, initiated before the listing of the hospital operator division as PT Siloam International Hospitals Tbk (Siloam) in September 2013 on the Indonesian Stock Exchange. LPKR owns 51% of Siloam and provides income support by way of subsidising c.80% of the rental for the hospitals. The rent paid to FIRT is denominated in SGD, leaving FIRT unaffected by currency movements between IDR and SGD. With LPKR lease expiring in August and December 2021 and Siloam’s operations on stable footing, LPKR could potentially step out of lease renewal talks, leaving negotiations directly between Siloam and FIRT. Given the c.80% rental gap, there is a risk that expiring leases will be re-negotiated with a lower quantum and/or on IDR-denominated terms.
Site Visit Highlights
Tertiary care hospitals provide highly specialised consultative care and handle more complex cases. They have higher revenue intensity per patient and margins compared to primary and secondary care hospitals. Each of FIRT’s hospital has its own “Centre of Excellence” (Figure 1), which focuses on selective branches of medicine such as Neuroscience, Cardiology and Oncology. The resident and practising doctors are some of the nation’s best in their respective fields, drawing patients from all the country.
Investment Actions
No stock rating or price target provided, as we do not have coverage on FIRT.
Descriptions of the visited assets
Siloam Hospitals Lippo Village (SHLV)
This 24-year old, 10-storey asset accounts for 12.7% of FY18 revenue and is located beside a community hospital. These two hospitals are the only hospitals in the Lippo Village Township. SHLV specialises in cardiology, neuroscience and orthopaedics and has a capacity of 274 beds.
Siloam Hospitals Kebon Jeruk (SHKJ)
SHKJ is a 28-year-old, 215-bed facility which contributed 7.2% of revenue in FY18. SHKJ is the oldest hospital asset in FIRT’s portfolio and specialises in Cardiology, Orthopaedics and Urology (Figure 11).
Mochtar Riady Comprehensive Cancer Centre (MRCCC)
MRCCC is a 29-storey nine-year-old asset specialising in Emergency & Trauma, Gastroenterology and Oncology with an extensive list of specialist doctors (Figure 15). The 334 bed hospital contributed 18.4% to FY18’s revenue. MRCCC handles end-to-end cancer diagnosis and treatment (Figure 16 and 17).
Imperial Aryaduta Hotel & Country Club (IAHCC)
IAHCC comprises a seven-storey hotel building and six blocks of terrace-styled villas. The 4-star 190 bed hotel and country club have undergone some minor AEI (lift upgrade) and room refreshments (Figure 18 and 19). IAHCC enjoys 80% occupancy and derives 65% of revenue from room sales and 35% from F&B operations, contributing 3.4% to FY18 revenue.
Comments
FIRT’s share price has fallen 10.1% in the last 12 months due to the downgrading of credit rating of Sponsor KPKR which caused FIRT’s total receivables to balloon 24.7% from S$26mn to S$32mn as of FY18. Since LPKR’s rights issue, the amount outstanding from LKRC stands at S$6mn. FIRT’s dividend yield (Figure 4) and P/NAV (Figure 5) is currently at the +1 standard deviation (s.d.) and -1 s.d. level respectively.
The main overhang on the share price remains the renewal of the master lease with LPKR. The lease renegotiation is further complicated by the lack of established market rents. Based on the reported figures in Siloam’s FY18 annual report, rental expense accounts for 30% of Siloam’s EBITDA, leaving a net profit of IDR26.4bn (S$2.6mn). The rental paid to LPKR for FY18 was IDR125.5bn (S$12.2mn), which constitutes 20% of the rent paid to FIRT. While we believe the properties in FIRT’s portfolio are of good quality and comparable to medical hubs globally, we are doubtful that Siloam would be able to afford renewing the leases at 30% of the rent and still remain profitable.
We understand from the management that the REIT has commenced discussions with LPKR and lease negotiations are expected to be completed 12 months before the lease expiry.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
